Features Navigation

(800) 825-0224 Live Demo
 ID NQF # Measure Type High Priority Measure? NQS Domain Data Submission Method(s)
449 1857 Process Yes Efficiency and Cost Reduction Registry

Measure Description

Percentage of female patients (aged 18 years and older) with breast cancer who are human epidermal growth factor receptor 2 (HER2)/neu negative who are not administered HER2-targeted therapies

Instructions

This measure is to be submitted a minimum of once per performance period for patients with breast cancer seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Measure Submission

The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data.

Numerator:

HER2-targeted therapies not administered during the initial course of treatment

NOTE: HER-2 targeted therapies are defined as Trastuzumab, Pertuzumab and TDM1.

Numerator Quality-Data Coding Options

Performance Met:

HER2-targeted therapies not administered during the initial course of treatment (G9827)

Performance Not Met:

HER2-targeted therapies administered during the initial course of treatment (G9828)

Denominator:

Adult women with breast cancer that are HER2 negative or HER2 undocumented

Denominator Criteria (Eligible Cases):
Female Patients aged ≥ 18 years on date of encounter

AND
Diagnosis of Breast Cancer (ICD-10-CM): C50. 011, C50. 012, C50. 019, C50. 111, C50. 112, C50. 119, C50. 211, C50. 212, C50. 219, C50. 311, C50. 312, C50. 319, C50. 411, C50. 412, C50. 419, C50. 511, C50. 512, C50. 519, C50. 611, C50. 612, C50. 619, C50. 811, C50. 812, C50. 819, C50. 911, C50. 912, C50. 919

AND
Patient encounter during performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215

AND
Two or more encounters at the reporting site

AND
HER-2/neu Negative or Undocumented/Unknown: G9825

AND NOT
DENOMINATOR EXCLUSION:
Patient transferred to practice after initiation of chemotherapy: G9826

 

Definitions:

Use the following definitions to determine HER-2/neu status-Positive:

IHC 3+ based on circumferential membrane staining that is complete, intense ISH positive based on:

  • Single-probe average HER2 copy number =6. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio = 2. 0 with an average HER2 copy number =4. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio = 2. 0 with an average HER2 copy number <4. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio < 2. 0 with an average HER2 copy number =6. 0 signals/cell

Equivocal:

IHC 2+ based on circumferential membrane staining that is incomplete and/or weak/moderate and within > 10% of the invasive tumor cells or complete and circumferential membrane staining that is intense and within = 10% of the invasive tumor cells ISH equivocal based on:

  • Single-probe ISH average HER2 copy number = 4. 0 and < 6. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio < 2. 0 with an average HER2 copy number = 4. 0 and < 6. 0 signals/cell

Negative:
IHC 1+ as defined by incomplete membrane staining that is faint/barely perceptible and within > 10% of the invasive tumor cells or IHC 0 as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within = 10% of the invasive tumor cells ISH negative based on:

Single-probe average HER2 copy number < 4. 0 signals/cell

Dual-probe HER2/CEP17 ratio < 2. 0 with an average HER2 copy number < 4. 0 signals/cell

Indeterminate:
Indeterminate if technical issues prevent one or both tests (IHC and ISH) from being reported as positive, negative, or equivocal.

Conditions may include:

  • Inadequate specimen handling,
  • Artifacts (crush or edge artifacts) that make interpretation difficult
  • Analytic testing failure

Transferred to Practice:
Patients who have transferred to the reporting practice after the initiation of HER2 targeted therapy at another practice. This prevents practices from being held accountable for another practices’ prior treatment decisions. The MIPS eligible clinician submitting the measure should have initiated the treatment for the denominator eligible patient.

Experience AdvancedMD Software in a Live Demo.

Schedule a short and personalized overview, guided by a live expert.

“If we are waiting for a delivery or in between surgeries, we can log in, check messages or patient information and send electronic prescriptions as needed. Mobility is a good thing, and certainly being able to coordinate care with our patients from multiple locations is definitely a plus.”

Lisbeth Chang, MD
Sunrise Women’s Medical Group

Read the story  ›

“[Our] patients are very well-educated and well-informed, and they want to see results quickly. The practice has to run extremely efficiently and be accessible to them. The nice thing about [AdvancedMD] is it has allowed me to be more efficient both in and out of the office. Now I don’t have to come back into the office, which is great for my family and everything else. It saves me a lot of time – probably an hour a day on the three days I work in the second office.”

Keith Berkowitz, MD
Center for Balanced Health

Read the story  ›

“The doctor who is not using AdvancedMD right now, is wasting his time.”

Armando Diez
Owner – Florida Pro Health

“With AdvancedMD we got everything in one package, and the ability to ensure that we get maximum allowable Medicaid reimbursement.”

Charlotte Kientzy
Practice billing manager